NCT01882803View on ClinicalTrials.gov

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

June 17, 2013

Primary Completion Date

November 18, 2020

Study Completion Date

November 18, 2020

Conditions
Indolent Non-Hodgkin Lymphoma
Interventions
DRUG

Duvelisib

Phosphoinositide-3-kinase (PI3K) inhibitor

Trial Locations (69)

1083

Budapest

1122

Budapest

1233

Sofia

1407

Sofia

1431

Sofia

1756

Sofia

4032

Debrecen

8500

Kortrijk

9000

Ghent

10021

New York

10043

Orbassano

11510

Rockville Centre

13005

Marseille

16132

Genova

20162

Milan

21052

Busto Arsizio

21100

Varese

21204

Baltimore

21229

Baltimore

24501

Lynchburg

25123

Brescia

28222

Madrid

30322

Atlanta

32308

Tallahassee

33076

Bordeaux

33705

St. Petersburg

37007

Salamanca

37203

Nashville

39916

Fort Myers

40138

Bologna

40207

Louisville

41124

Modena

43100

Parma

44718

Canton

47014

Meldola

47923

Rimini

48121

Ravenna

49933

Angers

60637

Chicago

63000

Clermont-Ferrand

63110

St Louis

69495

Pierre-Bénite

73104

Oklahoma City

73505

Lawton

75246

Dallas

80218

Denver

90603

Whittier

210603

Vitebsk

220013

Minsk

223040

Lyasny

224027

Brest

90095-6984

Los Angeles

02215

Boston

07731

Howell Township

07962

Morristown

01911

Philadelphia

M5G 2M9

Toronto

J8P7H2

Gatineau

H3T 1E2

Montreal

625-00

Brno

708-52

Ostrava-Poruba

0186

Tbilisi

08036

Barcelona

CF 14 4XW

Cardiff

Unknown

Chelsea

L7 8XP

Liverpool

NW1 2PG

London

W1G 6AD

London

SM2 5PT

Sutton

All Listed Sponsors
lead

SecuraBio

INDUSTRY

NCT01882803 - A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter